Pharmaceutical Executive-01-01-2013

As companies seek safety from empowered payers, bankrupt governments, and distracted regulators, success will come to those who understand how competition and technology are changing the way everything this industry does.

Courts across the country are making it easier to prove that a drug is unsafe, warning label notwithstanding.

Don't underestimate the importance of the first line manager.

New research sheds fresh light on a trend with serious consequences for the public health-not only in the United States but for patients worldwide.

Most executives across the pharmaceutical industry agree-Singapore does not represent any question marks in the future. Furthermore, Singapore's location is ideal for reaching markets east, west, north and south, which form the powerhouse that is Asia-Pacific.

Compliance officers have risen into management's highest ranks, by choice in some organizations, and by government decree in others. Either way, their importance as a strategic partner can hardly be understated.

Thankfully, the civil war is not a public relations issue for Big Pharma, but the long-term business implications for the Middle East region are cagey.

2013 may be a number associated with the fate of the luckless, but our annual review of the business and policy environment for Big Pharma suggests otherwise-as we near the midway point in the "tween" decade, there is good fortune in store for those with the perspective that comes with the long view.

Promoting the merits of private-sector drug innovation is no easy task-just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace.

FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.

Industry Forecast 2013, The Search for Safe Harbors